Cathepsin D-related disease-free interval in pT1 primary breast carcinomas: a pilot study.

Abstract

In order to address the heterogeneity of the pT1 breast cancer stages, we have been examining the natural and the clinical course of disease in relation to cathepsin D expression, as a molecular marker for the tumor progression that leads to metastasis. The original aim of our pilot study was to determine whether it was possible to distinguish high-risk from low-risk patients, on the basis of nonestrogen- vs. estrogen-regulated cathepsin D expression. Our results showed that estrogen-regulated cathepsin D expression could be useful as surrogate marker of node-positive status. Further, during the natural course of disease, none of 7 pT1N0 patients with tumors bearing nonestrogen-regulated cathepsin D expression developed metastasis. During the clinical course of disease, nonestrogen-regulated cathepsin D expression defined low-risk while estrogen-regulated cathepsin D expression defined high-risk pT1N+ subgroup of patients. Although there is no consensus with respect to metastasis-related prognostic value of cathepsin D expression, our pilot study implies its prognostic value in pT1 breast cancer patients and supports the hypothesis that cathepsin D may promote metastasis in this early stage of disease.

• Authors: D Nikolić-Vukosavljević, M Markićević, G Grujić-Adanja, A Petrović, K Kanjer, Z Nesković-Konstantinović
• Journal: Clinical & experimental metastasis (Clin Exp Metastasis) Vol. 22 Issue 4 Pg. 363-8 ( 2005) ISSN: 0262-0898 [Print] Netherlands
• PMID: 16170672 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Cathepsin D

Topics

• Biomarkers, Tumor (analysis, metabolism)
• Breast Neoplasms (diagnosis, pathology)
• Carcinoma (diagnosis, secondary)
• Cathepsin D (analysis, metabolism)
• Disease-Free Survival
• Female
• Humans
• Neoplasm Staging
• Pilot Projects
• Prognosis
• Risk Factors